CLINICAL TRIALS PROFILE FOR DERMACORT

All Clinical Trials for DERMACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	Roswell Park Cancer Institute	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	Children's Oncology Group	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.

Clinical Trial Conditions for DERMACORT

Condition Name

Condition Name for DERMACORT
Intervention	Trials
Untreated Childhood Acute Lymphoblastic Leukemia	2
B Acute Lymphoblastic Leukemia	2
Acute Lymphoblastic Leukemia	2
Recurrent Acute Myeloid Leukemia	1

Condition MeSH

Condition MeSH for DERMACORT
Intervention	Trials
Leukemia	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Leukemia, Lymphoid	3
Leukemia, Myeloid, Acute	2

Clinical Trial Locations for DERMACORT

Trials by Country

Trials by Country for DERMACORT
Location	Trials
United States	213
Canada	30
New Zealand	5
Australia	5
Puerto Rico	3

Trials by US State

Trials by US State for DERMACORT
Location	Trials
Illinois	7
Minnesota	6
Massachusetts	6
Wisconsin	6
New York	6

Clinical Trial Progress for DERMACORT

Clinical Trial Phase

Clinical Trial Phase for DERMACORT
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for DERMACORT
Clinical Trial Phase	Trials
Active, not recruiting	4
Recruiting	2
Completed	1

Clinical Trial Sponsors for DERMACORT

Sponsor Name

Sponsor Name for DERMACORT
Sponsor	Trials
National Cancer Institute (NCI)	8
Children's Oncology Group	4
Academic and Community Cancer Research United	1

Sponsor Type

Sponsor Type for DERMACORT
Sponsor	Trials
Other	8
NIH	8
Industry	1

Clinical Trials Update, Market Analysis, and Revenue Projections for DERMACORT

Last updated: June 21, 2026

DERMACORT is a topical corticosteroid brand name. No reliable, source-verifiable product-specific identifiers (active ingredient strength, dosage form, manufacturer, FDA label, ClinicalTrials.gov NCTs, or regulatory status) were provided, and no source-verifiable evidence is available here to produce a complete, accurate clinical-trials update, market sizing, or forward revenue projection for this specific DERMACORT product.

Key point: Without the exact DERMACORT formulation (active ingredient, strength, dosage form) and jurisdictional regulatory identity, any clinical-trials update and market forecast would be non-actionable and risk materially incorrect conclusions.

What clinical trials have been completed or ongoing for DERMACORT?

Featured snippet answer: None can be verified for “DERMACORT” as a uniquely identifiable drug product from the information provided.

How to map “DERMACORT” to the correct clinical record

A defensible trials update requires product-level matching across:

• Active ingredient (e.g., hydrocortisone, betamethasone, triamcinolone, clobetasol, etc.)
• Strength and vehicle (cream, ointment, lotion, gel, foam)
• Package labeling and manufacturer name
• Country of origin and trial registry (ClinicalTrials.gov, EU CTR, ISRCTN, etc.)

What outcomes matter for topical steroids

When a product is identifiable, clinical review should focus on:

• Eczema/dermatitis response endpoints (PASI, BSA, IGA scores)
• Time to onset and durability of response
• Safety outcomes (skin atrophy, ocular exposure risk, systemic absorption markers where applicable)
• Comparative outcomes vs active comparators (other topical steroids, steroid-sparing regimens)

What is the current market size and demand outlook for DERMACORT topical corticosteroids?

Featured snippet answer: Market size and demand outlook cannot be quantified for DERMACORT as a uniquely identifiable product without the active ingredient/strength and regulatory identity.

Market segmentation used for topical corticosteroid forecasts

A product-level forecast typically breaks down by:

• Therapeutic use: atopic dermatitis, contact dermatitis, inflammatory dermatoses
• Dosage form: cream vs ointment vs lotion (adherence and penetration profiles)
• Strength class: low, medium, high potency (labeling category drives reimbursement and prescribing)
• Channel: retail pharmacy, hospital, dermatology clinics
• Geography: US, EU5, UK, Canada, LATAM, MENA, APAC

Competitive pressure drivers for topical steroid brands

For a precise projection, the model needs:

• Generic penetration in the relevant strength class
• Payer coverage rules and step-edit policies
• Substitution likelihood at the point of sale (therapeutic equivalence, pack size)
• Formulation differentiation (vehicle tolerability, cosmetically acceptable bases)

When do generic or biosimilar versions of DERMACORT become available?

Featured snippet answer: Not determinable for DERMACORT without confirmed active ingredient/strength, listed patents, and regulatory status.

Exclusivity and patent-driven launch risk

A credible timeline requires:

• FDA Orange Book status (or EMA marketing authorization status if EU)
• Patent list presence and expiration dates
• Any Paragraph IV filings (US) or national challenges (EU)
• Settlement agreements affecting launch timing

What is the Orange Book status of DERMACORT?

Featured snippet answer: Not determinable because DERMACORT is not mapped to an FDA-listed application and strength/formulation identity in the provided information.

What an Orange Book review must include

For US exclusivity and patent coverage:

• Application number (ANDA/NDA)
• Patent types: composition, method of use, formulation/process
• Patent expiration dates and any pediatric exclusivity extensions
• Marketing exclusivity end date vs patent end date (often misread)

How strong is the patent estate for DERMACORT?

Featured snippet answer: Not assessable without the exact active ingredient/strength product identity and associated patent numbers.

Typical patent buckets to evaluate (once identified)

• Composition of matter (active ingredient or salts where relevant)
• Formulation patents (vehicle, concentration ranges, stability)
• Method-of-use patents (specific patient populations, dosing regimens)
• Manufacturing/process patents (critical for generic barrier assessment)

What generic entry risks exist for DERMACORT?

Featured snippet answer: Not quantifiable without:

• Patent/payer timeline in the relevant jurisdiction
• Identified strength class and closest generic substitutes
• Trial or bioequivalence requirements for the product form

Typical topical steroid generic risk factors

• High generics likelihood when patents are composition-weak or vehicle-generic
• Launch timing constrained by formulation/process patents
• OTC switching and pharmacy stocking patterns can move demand independent of patent expiry

What regulatory pathway and approval history apply to DERMACORT?

Featured snippet answer: Not determinable without mapping to an NDA/ANDA/BLA record and country of approval.

Regulatory milestones that change the forecast

Once identifiable, a forecast should tie to:

• Original approval date and label changes
• Variations (strength, vehicle reformulation)
• Safety label updates (long-term use warnings, atrophy precautions)
• Any REMS or risk management commitments (rare for topical steroids but label updates matter)

How does DERMACORT compare with other topical corticosteroids in efficacy and cost?

Featured snippet answer: No evidence-backed comparison can be made without the specific DERMACORT active ingredient and potency class.

Comparative factors used in market-access models

• Potency equivalence and label indications
• Vehicle tolerability and adherence
• Step-therapy positioning by payers
• Brand vs generic price ratio and formulary placement

Clinical trials timeline for DERMACORT: what to watch next

Featured snippet answer: No verifiable product-specific trials timeline can be produced for DERMACORT from the provided information.

What would drive future clinical readouts (once identified)

• Phase 3 comparative efficacy vs reference standards
• Formulation bridges (new vehicle, preservative systems, delivery system changes)
• Safety-focused studies (pediatric, sensitive sites, occlusion use)

Key Takeaways

• DERMACORT cannot be analyzed for clinical-trials status, market size, or revenue projections without a source-verifiable mapping to the exact drug product (active ingredient, strength, dosage form, manufacturer, and regulatory identity).
• A correct update requires tying “DERMACORT” to the specific FDA/EMA label entry and trial registry records; otherwise any forecast would be unreliable.

FAQs

1. How do I identify which DERMACORT product corresponds to a specific FDA or EMA record?
2. What endpoints are most used to compare topical corticosteroids in clinical trials?
3. How does potency class (low vs high) change payer restrictions for topical steroid brands?
4. What typically drives market share erosion for topical corticosteroid brands after generic launch?
5. How do vehicle changes (cream vs ointment vs lotion) affect substitution and demand?

References

No citations included because no source-verifiable, product-specific inputs were provided for DERMACORT.